In CAD, P2Y12 inhibitor vs. aspirin monotherapy reduces a composite CV outcome without increasing major bleeding
- PMID: 37931259
- DOI: 10.7326/J23-0090
In CAD, P2Y12 inhibitor vs. aspirin monotherapy reduces a composite CV outcome without increasing major bleeding
Abstract
Gragnano F, Cao D, Pirondini L, et al; PANTHER Collaboration. P2Y12 inhibitor or aspirin monotherapy for secondary prevention of coronary events. J Am Coll Cardiol. 2023;82:89-105. 37407118.
Conflict of interest statement
Comment on
- 
  
  P2Y12 Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary Events.J Am Coll Cardiol. 2023 Jul 11;82(2):89-105. doi: 10.1016/j.jacc.2023.04.051. J Am Coll Cardiol. 2023. PMID: 37407118
Publication types
MeSH terms
Substances
LinkOut - more resources
- Full Text Sources
- Miscellaneous
 
        